	Application No.	Applicant(s)
Notice of Allowability	10/016,858 Examiner	KOCH ET AL.
	San-ming Hui	1617
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>January 10, 2005</u> .		
2. The allowed claim(s) is/are <u>35,36,40,43,45-47 and 49-53</u> .		
3. The drawings filed on are accepted by the Examiner.		
<ul> <li>4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a)  All b)  Some* c) None of the:</li> <li>1.  Certified copies of the priority documents have been received.</li> <li>2.  Certified copies of the priority documents have been received in Application No</li> <li>3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul>		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
•		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. ☐ Notice of Informal Pa	atent Application (PTO-152)
2.  Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0-Paper No./Mail Date	Paper No./Mail Date 8), 7. ☐ Examiner's Amendm	
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	nt of Reasons for Allowance
of Biological Material	9.  Other	
		•

Application/Control Number: 10/016,858

Art Unit: 1617

## **REASONS FOR ALLOWANCE**

Claims 35, 36, 40, 43, 45-47, and 49-53 are pending.

The following is an examiner's statement of reasons for allowance: applicant's rebuttal arguments averring the cited prior arts' failure to provide reasonable expectation of success to employ the herein claimed low dose estradiol regimen, i.e.,  $10\mu g$  or  $5\mu g$  once or twice weekly, for treating atrophic vaginitis have been considered, and are found persuasive to withdraw the outstanding rejections under 35 USC 103.

The prior art's teachings lack the suggestion to lower the dose of estradiol in tablet forms. The state of the art disclosed in Santen states, "the lowest dose of vaginal E2 reported to be effective for treating vaginal atrophy is 5-10µg/day, delivered via a silastic ring." Such statement indicates that the dosing regimen recited in the instant claims, i.e., 5 or 10 µg once or twice weekly, is actually lower than the lowest therapeutic dosage of estradiol known in the art. Considering the effective regimen in the instant specification, such low dose regimen of estradiol is effective in treating atrophic vaginitis. Therefore, the applicant's data in the instant specification demonstrates unexpected effectiveness of treating atrophic vaginitis.

Claims 35, 36,40,43,45-47, and 49-53 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 10/016,858

Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-0626. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Examiner

Art Unit 1617